- Letter to the Editor
Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab
Clinical and Translational Allergyvolume 8, Article number: 37 (2018)
We report two patients with normocomplementaemic urticarial vasculitis with impressive response to omalizumab. This contrasts recent reports on hypocomplementaemic urticarial vasculitis syndrome, highlighting the need for clinical trials of omalizumab in normocomplementaemic urticarial vasculitis.
To the Editor:
Urticarial vasculitis is a cutaneous small vessel vasculitis characterised by erythematous patches or wheals persisting for greater than 24 h. Microscopic early appearances are of a neutrophilic leukocytoclastic vasculitis, which is thought to develop later into a lymphocytic vasculitis. It is associated with itching or burning, which can significantly reduce quality of life.
The presence of systemic features, involving the musculoskeletal, renal, pulmonary and/or gastrointestinal systems, is primarily linked to hypocomplementaemic urticarial vasculitis (HUV; syn. hypocomplementaemic urticarial vasculitis syndrome), for which anti-C1q auto-antibodies are a marker, and is increasingly seen as a separate entity to normocomplementaemic urticarial vasculitis (NUV).
Cutaneous symptoms of urticarial vasculitis are treated with oral antihistamines and can also require non-steroidal anti-inflammatory drugs, oral corticosteroids, colchicine, chloroquine and/or dapsone. Treatment is challenging due to the limited effect and side effects of current treatments.
Chronic spontaneous urticaria, where individual lesions persist for less than 24 h, has been shown to respond to omalizumab, a humanised, anti-IgE monoclonal antibody . Clinically, urticarial vasculitis is often indistinguishable from chronic spontaneous urticaria unless lesion duration is carefully monitored, requiring histology for diagnosis, and may therefore be underdiagnosed. It could be extrapolated that amongst the chronic urticaria cases responding to omalizumab are also unrecognised cases of urticarial vasculitis.
There are only a few, isolated case reports of omalizumab being used in urticarial vasculitis with conflicting responses. Here, we present two cases of urticarial vasculitis with impressive therapeutic response immediately to a single dose of omalizumab.
A 63 year-old Australian male developed an urticarial rash in August 2016 after removing carpet in his house. Past medical history was significant for ischaemic heart disease, hypercholesterolaemia, hypertension and Barrett’s oesophagus. He was on several medications (no recent changes) and had no known allergies. On examination, there were widespread urticarial plaques and papules with signs of post-inflammatory hyperpigmentation, which persisted in the same areas over 24 h (Fig. 1a). He’d had an incomplete response to oral antihistamines (cetirizine 10 mg once daily and promethazine 12.5 mg twice daily) and to oral corticosteroids (prednisone 50 mg once daily with failure to taper below 15 mg/day over a month period) with ongoing pruritus continuing to affect his sleep.
Routine blood tests including auto-antibodies, tumour markers and C3/C4 levels were normal, aside from likely steroid-induced leukocytosis and fasting hyperglycaemia. CT abdomen/pelvis revealed no significant findings. A skin biopsy revealed perivascular lymphocytes and neutrophils, with erythrocytic extravasation and leukocytoclasis, as demonstrated by a basophilic hue to the collagen surrounding vessels in some foci. These histological findings were consistent with urticarial vasculitis (Fig. 1e, f).
For the next 8 months, he had ongoing symptoms requiring high-dose systemic corticosteroids (cumulative dose 5460 mg prednisone with signs of glucocorticoid toxicity including raised BMI and impaired glucose tolerance), narrow band UVB therapy three times weekly, hydroxychloroquine (200 mg twice daily), colchicine (500 mcg twice daily) and sodium cromoglicate (100 mg once daily). In April 2017, he achieved a complete remission of his symptoms when he was started on omalizumab at a dose of 300 mg (150 mg × 2) subcutaneously once every four weeks. On review 4 weeks after the initial dose, his UAS7 (urticaria activity score over 7 days) had decreased from 30 to 0 and itch score had decreased from 9 to 0. Steroids and UV therapy were tapered down and stopped. To the present date (May 2018), he continues on omalizumab and remains symptom-free on omalizumab monotherapy.
The second case, a 72 year-old German male had a 7 year history of chronic wheals persisting over 24 h (Fig. 1c) and pronounced itching, which were characterised histologically as urticarial vasculitis (Fig. 1g, h). Investigations were normal including X-ray of the lungs and abdominal ultrasound, and there were no indications of extra-cutaneous symptoms or of other conditions responsible for causing urticarial vasculitis.
He had ongoing symptoms despite high dose desloratadine (5 mg QDS), dapsone (100 mg once daily) over 6 months, chloroquine (250 mg once daily) over 3 months and methotrexate (15 mg once weekly) over 6 weeks—stopped early due to deranged liver function. In November 2015, he was started on omalizumab monotherapy, also at 300 mg (150 mg × 2) subcutaneously once every 4 weeks. On review at 4 weeks, his UAS 7 had reduced from 42 to 1. Four weeks after a further dose, he was entirely symptom-free and continues treatment with omalizumab monotherapy at the same dose.
To our knowledge, there have been only a few case reports of omalizumab in urticarial vasculitis. Table 1 shows that some studies showed significant improvement in symptoms in male and female patients with NUV alone [2,3,4,5,6] and in combination with systemic lupus erythematosus  and Churg–Strauss syndrome . However, studies in patients with HUV show conflicting results: one with major organ involvement showed only minimal improvement , whereas a patient without major organ involvement showed complete resolution. None of these studies reported adverse events in relation to omalizumab.
Interestingly, these case reports suggest that omalizumab may be effective in NUV, rather than HUV. Omalizumab’s pharmacological mode of action is to block the effects of IgE on mast cells, hence reducing inflammation. Rather, HUV has been shown in case reports to respond to interleukin-1 receptor antagonism with anakinra or canakinumab. It would follow that IgE could play a pivotal role in the pathogenesis of NUV, but not in HUV with major organ involvement, and that the two disease categories could thus be related to different pathophysiological processes. It is possible that IgE and mast cells may be more central in the pathogenesis of NUV than vascular damage due to immune complex deposition, indicating that NUV is rather on the spectrum of chronic spontaneous urticaria. This would mean that the conventional histological definition of urticarial vasculitis may need revision. Although there may be a lymphocytic phase in the resolution of a leucocytoclastic vasculitis, there is no known evidence that neutrophilic leucocytoclastic vasculitis consistently develops into a lymphocytic vasculitis. These present cases in the context of the literature suggest that omalizumab is safe and effective in patients with normocomplementaemic urticarial vasculitis, but not hypocomplementaemic urticarial vasculitis syndrome. This sheds light on the distinct pathogenetic mechanisms of these two disease entities and may encourage clinical trials with omalizumab in normocomplementaemic urticarial vasculitis. Treatment of these patients with omalizumab would not least allow avoidance of glucocorticoid-induced toxicity.
hypocomplementaemic urticarial vasculitis
normocomplementaemic urticarial vasculitis
systemic lupus erythematosus
urticaria activity score
Saini S, Rosen K, Hsieh H, Wong D, Conner E, Kaplan A, Spector S, Maurer M. A randomized, placebo controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128(567–573):e1.
Diez L, Tamayo L, Cardona R. Omalizumab: opción terapéuticaen el tratamiento de la urticaria crónica espontánea de difícil control con vasculitis asociada. Reporte de trescasos. Biomédica. 2013;33:503–12.
Sussman G, Hébert J, Barron C, Bian J, Caron-Guay R, Laflamme S, Stern S. Real-life experiences with omalizumab for the treatment of chronic urticaria. Ann Allergy Asthma Immunol. 2014;112:170–4.
Ghazanfar M, Thomsen S. Omalizumab for urticarial vasculitis: case report and review of the literature. Case Rep Dermatol Med. 2015;2015:1–3.
Fueyo-Casado A, Campos-Muñoz L, González-Guerra E, Pedraz-Muñoz J, Cortés-Toro J, López-Bran E. Effectiveness of omalizumab in a case of urticarial vasculitis. Clin Exp Dermatol. 2017;42:403–5.
Kai A, Flohr C, Grattan C. Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis. Clin Exp Dermatol. 2014;39:651–2.
Del Pozo MER, Martínez Saenz N, Vera J, Tiro J. 274 vasculitic urticaria treated with omalizumab. Case report. World Allergy Organ J. 2012;5:S89.
Varricchi G, Detoraki A, Liccardo B, Spadaro G, de Paulis A, Marone G, Triggiani M. 275 efficacy of omalizumab in the treatment of urticaria-vasculitis associated to Churg–Strauss syndrome. World Allergy Organ J. 2012;5:S89–90.
Aurich S, Simon J, Treudler R. Omalizumab does not improve skin lesions in a patient with hypocomplementemic urticarial vasculitis syndrome. J Eur Acad Dermatol Venereol. 2017;31:e395–7.
Nucera E, Basta F, Buonomo A, Mezzacappa S, Margiotta D, Antonelli Incalzi R, Schiavino D. A case of hypocomplementemic urticarial vasculitis syndrome successfully treated with omalizumab. J Investig Allergol Clin Immunol. 2017;27:382–4.
MdB and GH contributed equally to this work. All authors read and approved the final manuscript.
K Hartmann has received consultancy fees from ALK-Abelló, Blueprint, Deciphera and Novartis and has received lecture fees from ALK-Abelló, Novartis and Shire. D. Murrell has received lecture fees from Novartis. M. de Brito has received fees for educational services from Abbvie.
Availability of data and materials
Consent for publication
Written and informed consent for publication was obtained from both patients.
Ethics approval and consent to participate
Written and informed consent was obtained from both patients to participate.
No funding has been received for this manuscript.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.